{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P42345",
      "entity_text" : "mTOR",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:216239",
      "entity_text" : "Sorafenib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Therapeutic agents targeting VEGF or mTOR signaling, such as Sorafenib XREF_BIBR, Pazopanib XREF_BIBR, Sunitinib XREF_BIBR, Bevacizumab XREF_BIBR, and Everolimus XREF_BIBR, have been successfully developed and clinically useful XREF_BIBR.",
  "reading_complete" : "2020-08-03T09:49:32Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T09:48:15Z",
  "trigger" : "signaling",
  "evidence" : [ "mTOR signaling, such as Sorafenib" ],
  "pmc_id" : "5399579",
  "score" : 0
}